Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

23 Press Releases
DateTitleCompany
05 Dec 13 European Medicines Agency Approves Once Every Two Weeks Dosing Option For Hizentra®? (Human Normal Immunoglobulin, SCIg) CSL Behring UK Ltd,
Published by
Business Wire
03 Jul 12 CSL Behring launches new Hizentra®? Dosing Calculator App for Healthcare Professionals on the move CSL Behring UK,
Published by
CSL Behring UK Ltd
28 Jun 12 CSL Behring launches new Beriplex® P/N Dosing Calculator App for Healthcare Professionals on the move CSL Behring,
Published by
Munro & Forster
24 Feb 11 CSL Behring Receives FDA Approval to Extend Shelf Life of Hizentra® to 30 Months CSL Behring,
Published by
Business Wire
18 Aug 10 CSL Behring Receives FDA Approval to Extend Shelf Life of Hizentra® from 18 Months to 24 Months CSL Behring,
Published by
Business Wire
09 Jun 10 Unique Hereditary Angioedema e-Learning Initiative Launched at 29th Congress of the European Academy of Allergy and Clinical Immunology CSL Behring,
Published by
PR Newswire
13 Apr 10 CSL Behring Seeking Proposals for LEAD Grants to Support Patient Advocacy Efforts CSL Behring,
Published by
Business Wire
05 Mar 10 CSL Behring Receives FDA Approval of HizentraTM, First 20 Percent Subcutaneous Immunoglobulin Therapy CSL Behring,
Published by
Business Wire
01 Mar 10 New Data Show IgPro20 Delivers Highest Available Subcutaneous Ig Concentration with Tolerability Comparable to Current Treatments CSL Behring,
Published by
Business Wire
01 Mar 10 European Data Suggest Switching Patients to IgPro20 May Significantly Reduce Drug Administration Volume CSL Behring,
Published by
Business Wire
01 Mar 10 IgPro20, the First 20 Percent Subcutaneous Immunoglobulin, Demonstrates Efficacy against Infections While Maintaining Tolerability in Patients with Primary Immunodeficiency CSL Behring,
Published by
Business Wire
05 Feb 10 Global SWIFT Studies Will Evaluate Safety and Efficacy of CSL Behring's Biostate(R) for von Willebrand Disease and Hemophilia A CSL Behring,
Published by
PR Newswire
21 Dec 09 Findings of Australian Trial of CSL’s Pandemic (H1N1) 2009 ‘Swine’ Flu Vaccine in Children Published in Journal of the American Medical Association (JAMA) CSL Limited,
Published by
Business Wire
11 Dec 09 Vaccine to treat gum disease on the way CSL,
Published by
PharmiWeb.com
09 Dec 09 CHANGES TO CSL SENIOR EXECUTIVE GROUP CSL,
Published by
PharmiWeb.com
07 Oct 09 Vaccines delivered on time across Australia for largest national immunisation program on record CSL Biotherapies,
Published by
PharmiWeb.com
21 Sep 09 Panvax® H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration CSL,
Published by
PharmiWeb.com
16 Jul 09 CSL Backs Key Training Program for Health and Medical Sciences CSL,
Published by
PharmiWeb.com
01 Jul 09 Trial of Novel H1N1 ‘Swine’ Flu candidate vaccine to take place in Adelaide CSL,
Published by
PharmiWeb.com
10 Jun 09 CSL and Talecris Biotherapeutics Agree to Terminate Merger Agreement CSL,
Published by
PharmiWeb.com
29 May 09 CSL reaffirms its commitment to supply Australia with Novel Influenza A (H1N1) ‘Swine Flu’ Vaccine CSL,
Published by
PharmiWeb.com
26 May 09 CSL meets with US Federal Trade Commissioners regarding Talecris Acquisition CSL,
Published by
PharmiWeb.com
21 Apr 09 CSL Recruitment - 1995 - 2009, 15 Years of Success CSL Recruitment
Advertising